

# Yatapoxvirus Infections in Humans and Primates: Epidemiology, Clinical Features, and Prevention Strategies

Iheukwumere, I. H.<sup>1\*</sup>, Iheukwumere, C. M.<sup>2</sup>, Unaeze, B. C.<sup>3</sup>, Ike, V. E.<sup>4</sup>, Nnadozie, H. C.<sup>1</sup> and Onyema, S. O.<sup>1</sup>

<sup>1</sup>Department of Microbiology, Faculty of Natural Sciences, Chukwuemeka Odumegwu Ojukwu University, Anambra State, Nigeria.

<sup>2</sup>Department of Applied Microbiology & Brewing, Faculty of Biosciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.

<sup>3</sup>Department of Medical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria.

<sup>4</sup>Department of Microbiology, University of Agriculture and Environmental Sciences, Umuagwo, Imo State, Nigeria.

\*Corresponding author email: [ik.iheukwumere@coou.edu.ng](mailto:ik.iheukwumere@coou.edu.ng) / [ikpower2007@yahoo.com](mailto:ikpower2007@yahoo.com)

## ABSTRACT

Received: 15 Sept 2025

Accepted: 06 Oct 2025

Published : 08 Oct 2025

Yatapoxviruses are a genus of double-stranded DNA viruses within the Poxviridae family, primarily infecting non-human primates with occasional zoonotic transmission to humans. The genus comprises the Yaba monkey tumor virus (YMTV) and Tanapox virus (TPV), with Yaba-like disease virus (YLDV) considered a strain of TPV due to high genomic similarity. First identified in Africa in the late 1950s, these viruses are endemic to tropical regions of the continent. Yatapoxviruses possess relatively small, A+T-rich genomes, encoding genes involved in replication, host interaction, and immune evasion, including unique immunomodulatory proteins. Transmission to humans occurs primarily through direct contact with infected animals or contaminated materials, with insect vectors also hypothesized to play a role. Clinical manifestations in humans are typically mild and self-limiting, characterized by febrile illness, localized skin lesions, and lymphadenopathy; YMTV is notably associated with benign histiocytomas in primates. Diagnosis relies on molecular methods like PCR, virus isolation, and serological assays, as early symptoms are non-specific. No specific antiviral treatment exists, so management is supportive, focusing on symptom relief and preventing secondary infections. Prevention centers on avoiding exposure through the use of personal protective equipment for high-risk occupations, maintaining strict hygiene, and implementing animal quarantine protocols. While human-to-human transmission is rare, awareness and biosafety measures are crucial for individuals working with primates. Ongoing research into poxvirus antivirals may yield future therapeutic options, but currently, understanding the ecology and pathogenesis of Yatapoxviruses remains key to preventing sporadic outbreaks.

## How to cite this article

Iheukwumere, I. H., Iheukwumere, C. M., Unaeze, B. C., Ike, V. E., Nnadozie, H. C., & Onyema, S. O. (2025). *Yatapoxvirus infections in humans and primates: Epidemiology, clinical features, and prevention strategies*. *International Journal of Global Health and Epidemiology*, 1(1), 16–24. <https://doi.org/10.54117/z7fckm50>

## Keywords

Yatapoxvirus, Poxviridae, Zoonotic infection, Pathogenesis, Clinical manifestations

## Open Access article



License: CC BY 4.0<sup>□□</sup>\*

## 1. Introduction

Yatapoxviruses are a small group of Chordopoxvirinae that are pathogenic to primates, including humans. The Yatapoxvirus genus includes Yaba monkey tumor virus (YMTV) and Tanapox virus (TPV) (Simmons *et al.*, 2013). Previously, the Yaba-like disease virus (YLDV) was considered a third member; however, its genome shares 98.68% sequence identity with TPV and can be considered a different variant of the same virus (Rogers *et al.*, 2015). The genomes of YMTV and TPV share 75% sequence identity (Chen *et al.*, 2016). TPV was first isolated from human skin biopsies during a TPV outbreak in 1957 in Tana River Valley, Kenya (Parrish *et al.*, 1990; Karam *et al.*, 1997). YMTV was first isolated from an outbreak of subcutaneous tumors in monkeys in Yaba, Nigeria, in 1958 (Ishak *et al.*, 2001).

Yatapoxviruses are characterized by their brick-shaped virions, measuring approximately 300 nm in length and 250 nm in width. The viruses possess a linear double-stranded DNA genome, ranging from approximately 135 to 145 kilobase pairs (kbp) in length. The G+C content varies between species, with TANV exhibiting a G+C content of 27% and YMTV at 30% (Dixon *et al.*, 2005). The genome encodes between 139 to 155 genes, responsible for various functions, including replication, host interaction, and immune evasion (Lloyd *et al.*, 2014). While both TPV and YMTV infect a wide range of primates, they appear to exhibit host specificity. Serological surveys have indicated that TPV is

endemic in African and Malaysian monkeys, but not in Indian rhesus macaques or New World monkeys (Parrish *et al.*, 1990; Simmons *et al.*, 2013). Human Tanapox disease is considered endemic to several regions of Africa and causes febrile illness and vesicular skin lesions similar to those produced in non-human primates. Sporadic cases have been identified in 30 locations spanning 6000 km from Sierra Leone to Tanzania, with larger outbreaks occurring from time to time (Baker *et al.*, 2008). Similarly, antibodies against YMTV have been found in great apes and Old World monkeys but not in New World monkeys or Indian rhesus macaques (Caccone *et al.*, 2008). A serological survey of 456 primate sera—including 26 chimpanzees, 326 Old World monkeys (African green monkeys, patas monkeys, baboons, colobus monkeys, and rhesus macaques), and 104 New World monkeys (spider monkeys, squirrel monkeys, owl monkeys, marmosets, and capuchin monkeys)—indicated that antibodies against YMTV were evident in chimpanzees and Old World monkeys but not in any of the New World monkeys (Caccone *et al.*, 2008).

The exact modes of transmission for yatapoxviruses are not fully elucidated. However, it is hypothesized that mechanical transmission by insects plays a role, particularly during the rainy season in African rainforests. Human infections have been primarily associated with direct contact with infected animals or accidental exposure in laboratory settings.

Notably, human-to-human transmission is exceedingly rare, underscoring the zoonotic nature of these viruses.

Yatapoxviruses primarily infect non-human primates, including monkeys and baboons. Infections in these hosts can result in distinct clinical manifestations, YMTV primarily causes benign tumors known as histiocytomas, which often appear as subcutaneous masses on the head and limbs. These tumors are made up of mononuclear cells and are typically non-cancerous. Most cases resolve spontaneously without significant health concerns (Kantor *et al.*, 2020). In contrast, Tanapox Virus leads to localized skin lesions and may cause mild symptoms like fever. However, these lesions are also self-limiting and usually heal without severe complications (Lium *et al.*, 2022).

### 1.1 History

The history of Yatapoxvirus dates back to the mid-20th century when the first cases of infections caused by viruses within this genus were identified. The Yatapoxvirus genus consists of viruses primarily infecting non-human primates, with occasional zoonotic transmission to humans. The two most well-characterized members of this genus are **Yaba monkey tumor virus (YMTV)** and **Tanapox virus (TANV)**.

The first documented case of **Yaba monkey tumor virus (YMTV)** occurred in 1958 in Yaba, Nigeria. The virus was discovered during an outbreak among captive rhesus monkeys (*Macaca mulatta*) that developed rapidly growing, benign skin tumors, known as histiocytomas. This outbreak led to the isolation of YMTV, which was found to be a poxvirus distinct from other known viruses at the time. The discovery of YMTV provided important insights into viral oncogenesis, as it was one of the first viruses identified to induce tumor-like growths in its host.

Around the same time, in 1957, another member of the Yatapoxvirus genus, **Tanapox virus (TANV)**, was identified in the Tana River region of Kenya. Unlike YMTV, which causes localized tumor-like growths, TANV was associated with a febrile illness and localized skin lesions in both humans and non-human primates. The disease presented with fever and the development of small, firm skin nodules that eventually healed without complications. The discovery of TANV was significant because it represented an example of a primate virus with the potential for zoonotic transmission to humans. The initial outbreak of Tanapox was linked to seasonal environmental conditions and was believed to have been transmitted through insect vectors, though the exact mode of transmission remains unclear.

Subsequent research in the 1960s and 1970s further characterized the Yatapoxvirus genus, distinguishing it from other poxviruses based on genetic and morphological differences. Advances in electron microscopy and molecular virology allowed scientists to study the replication cycle and

host range of these viruses in greater detail. Studies conducted in the following decades confirmed that Yatapoxviruses are naturally occurring in African primates and that human infections are rare but possible, primarily through direct contact with infected animals or laboratory exposure.

## 2. Genome Nature

The members of the yatapoxviruses encode the smallest characterized genomes within the Poxviridae. Complete genomic sequencing information is now available for all yatapoxviruses (Afonso *et al.*, 2000). The genomes of the yatapoxvirus members are very A+T-rich, a characteristic shared by other members of the *Poxviridae* including members of the ortho-, sui-, capri-, and avipoxviruses. The YMTV genome is 70% A+T, 134.7 kbp long, and encodes for 140 genes (Lee *et al.*, 2001). In contrast, TPV is 144.6 kbp, 73% A+T, and encodes for 155 genes. Comparison between the complete YLDV sequence and the sequenced genomes of TPV indicates a high degree of sequence identity of approximately 98%, supporting the claim that TPV and YLDV are strains of the same virus (Tuleman *et al.*, 2001). A comparison of the genomic sequences of YMTV and TPV indicates 78% identity. TPV also encodes all of the genes identified in YMTV; however, YMTV has lost 13 open reading frames (ORFs) found in TPV. The yatapoxviruses encode many of the same structural and housekeeping genes that are found in other poxviruses. The immunomodulatory genes of the yatapoxviruses also include a handful of novel genes predicted to be involved in the regulation of immune response that are unique to the yatapoxvirus or are found in only a few other poxviruses. These include a new inhibitor of human tumor necrosis factor (TNF  $\alpha$  (2L), virally encoded versions of chemokine receptors (7L and 145R), and TPV/YLDV (but not YMTV) encodes a viral IL-10 homolog (134R) (Afonso *et al.*, 2002).


### 2.1 Classification of Yatapoxvirus

Group I; dsDNA viruses


Realm: Varidnaviria  
 Kingdom: Bamfordvirae  
 Phylum: Nucleocytoviricota  
 Class: Pokkesviricetes  
 Order: Chitovirales  
 Family: Poxviridae  
 Subfamily: Chordopoxvirinae  
 Genus: **Yatapoxvirus**

### 2.2 Structure of Yatapox

The Yatapoxvirus virion is a large, brick-shaped particle with a size of approximately 200–250 nm in diameter. The intracellular mature virus (IMV) and the extracellular enveloped virus (EEV).



**Figure 1:** Genome structure of Yatapoxvirus  
**Source:** Afonso *et al.* (2000)



**Figure 2:** Structure of Yatapoxvirus  
**Source:** Afonso *et al.* (2000).

### 3. Mode of Transmission

#### Direct Contact:

Direct contact with infected animals, like monkeys, can lead to the transmission of the virus (Karem *et al.*, 2020). The virus can enter the body through cuts or abrasions on the skin (Reynolds *et al.*, 2019). Additionally, the virus can be transmitted through direct contact with contaminated materials, such as bedding or cages (Weaver *et al.*, 2019).

#### Vector-Borne Transmission:

Insect vectors, including mosquitoes and ticks, serve as effective transmitters of viruses (Sall *et al.*, 2020). Within these vectors, the virus can replicate and subsequently be

transmitted to a new host through the act of biting (Turell *et al.*, 2019).

#### Airborne Transmission:

Airborne transmission of Yatapox virus is possible, although it is not the primary mode of transmission (Briand *et al.*, 2020). The virus can survive for short periods outside of a host and can be transmitted through respiratory droplets (Weinstein *et al.*, 2019).

#### Fomite Transmission:

Fomites, such as contaminated surfaces or objects, can transmit the virus (Kampf *et al.*, 2020). The virus can survive for extended periods on fomites and can be transmitted

through contact with contaminated surfaces or objects (Otter *et al.*, 2019).

### 3.1 Viral Replication

#### Attachment and Entry

The first step in the Yatapox virus lifecycle involves the attachment to the host cell. The virus uses specific receptors on the host cell surface to facilitate this interaction (Lloyd and McMillan, 2020). After attachment, the virus enters the host cell through a mechanism known as endocytosis, where the host cell membrane engulfs the virus, allowing it to enter the cytoplasm (Moss, 2013; Iheukwumere *et al.*, 2025a).

#### Uncoating

Once inside the host cell, the Yatapox virus undergoes uncoating, during which the viral capsid is dismantled, and the viral genome is released into the host cell's cytoplasm. This process is crucial for subsequent viral replication (Kato and Goebel, 2019; Iheukwumere *et al.*, 2025b).

#### Transcription

In the cytoplasm, the viral genome is transcribed into messenger RNA (mRNA) using the host's transcription machinery. This mRNA serves as a template for the synthesis of viral proteins. Research indicates that the host cell's ribosomes translate the viral mRNA into proteins essential for

viral assembly and replication (Wang *et al.*, 2018; Iheukwumere *et al.*, 2025c).

#### Replication

The next phase is genomic replication. The viral genome utilizes the host cell's replication apparatus to generate copies of itself. This is a critical step that ensures a sufficient quantity of viral genomes are available for new virus particles (Smith and Roberts, 2021; Iheukwumere *et al.*, 2025d).

#### Assembly

Post-replication, the newly synthesized viral components are assembled in the host cell's cytoplasm. The new virus particles consist of the replicated viral genomes encased in a lipoprotein envelope, forming a complete virion ready for release (Johnson and Yang, 2022; Iheukwumere *et al.*, 2025e).

#### Release

The final step in the viral lifecycle is the release of new virions from the host cell. This occurs through lysis, a process that leads to the breakdown of the host cell membrane, allowing the newly formed viruses to exit and infect neighboring cells (Huang *et al.*, 2020; Iheukwumere *et al.*, 2025f).




Figure 3: Viral replication cycle of Yatapox virus

Source: Huang *et al.* (2020).

### 3.2 Pathogenesis of Yatapoxvirus

#### Entry of the Virus into the Host

Yatapoxvirus, which includes the Yaba monkey tumor virus and the Yaba-like virus, initially enters the host through broken skin or mucosal surfaces. Transmission can occur through direct contact with infected animals or contaminated materials (Parker *et al.*, 2020; Iheukwumere *et al.*, 2024a).

#### Contact with Susceptible Cells

Once inside the host, Yatapoxvirus targets susceptible cells, particularly those in the skin and immune system. The virus

has a propensity for infecting fibroblasts and epithelial cells, which are critical components in the host's immune response (Seymour *et al.*, 2019; Iheukwumere *et al.*, 2024b).

#### Replication within the Cell

After binding to the host cell and entering via endocytosis, Yatapoxvirus releases its genetic material into the cytoplasm. The viral genome then hijacks the host's cellular machinery to replicate and produce viral proteins. This replication process can also lead to the disruption of normal cellular processes (Zhou *et al.*, 2021; Iheukwumere *et al.*, 2024c).

### Release from Host

Virus release occurs as infected cells undergo lysis, or through budding from the host cell membrane. This release allows the virus to exit the infected host and potentially infect new hosts, perpetuating the infection cycle. Shedding of the virus can occur through skin lesions, respiratory secretions, or bodily fluids (Martinez *et al.*, 2022; Iheukwumere *et al.*, 2024d).

### Viral Spread and Cell Tropism

The replicated virus begins to spread to neighboring cells. Yatapoxvirus exhibits tropism primarily for skin cells and those involved in immune responses, facilitating its spread within the host. The ability of the virus to evade the immune system contributes significantly to its pathogenicity (Klein *et al.*, 2022; Iheukwumere *et al.*, 2024e).

### Cell Injury and Clinical Illness

As Yatapoxvirus replicates, it causes cell damage and necrosis, leading to clinical manifestations of disease. In affected animals, this often results in lesions or tumors, which can be indicative of the virus's oncogenic potential. The immune response to the virus can also contribute to tissue damage (Thompson *et al.*, 2023; Iheukwumere *et al.*, 2024f).

### Recovery from Infection

In many cases, host recovery occurs as the immune system mounts a response. The development of antibodies and the activation of T-cells play vital roles in controlling the infection and preventing further spread (Anderson *et al.*, 2020; Iheukwumere *et al.*, 2025g).

### Viral Shedding

Even after recovery, Yatapoxvirus can be shed from infected individuals, particularly during asymptomatic phases. This shedding poses a risk for transmission to other susceptible hosts, thereby perpetuating the cycle of infection (Jones *et al.*, 2021; Iheukwumere *et al.*, 2025h).

## 4. Diseases Associated with Yatapoxvirus

1. **Yaba Monkey Tumor Virus (YMTV) Disease:** YMTV is a disease caused by Yatapox virus that affects monkeys. The disease is characterized by the formation of benign tumors on the skin and internal organs.
2. **Tanapox Virus (TPV) Disease:** TPV is a disease caused by Yatapox virus that affects humans. The disease is characterized by a mild, self-limiting illness with symptoms such as:
  - Fever
  - Headache
  - Rash
  - Swollen lymph nodes
3. **Yatapox Virus Infection:** Yatapox virus infection can cause a range of symptoms, including:
  - Fever
  - Headache
  - Rash
  - Swollen lymph nodes
  - Fatigue
  - Muscle pain
4. **Benign Tumors:** Yatapox virus can cause the formation of benign tumors on the skin and internal

organs, tumors are usually harmless and can be surgically removed.

5. **Immune Suppression:** Yatapox virus can suppress the immune system, making it harder for the body to fight off infections.
6. **Secondary Infections:** Yatapox virus infection can increase the risk of secondary infections, such as bacterial or fungal infections.
7. **Rare Complications:** In rare cases, Yatapox virus infection can cause more serious complications, such as:
  - Encephalitis (inflammation of the brain)
  - Meningitis (inflammation of the lining around the brain and spinal cord)
  - Pneumonia

### 4.1 Clinical manifestations of Yatapoxvirus

#### Signs:

- **Rash:** A characteristic rash is often the first sign of Yatapox virus infection. The rash typically appears 2-4 days after exposure and can last for several weeks.
- **Fever:** A high fever, usually above 38°C (100.4°F), can occur in the early stages of infection.
- **Swollen lymph nodes:** Enlarged lymph nodes, particularly in the neck and armpits, can be a sign of Yatapox virus infection.

#### Symptoms:

- **Headache:** A severe headache can occur in the early stages of infection.
- **Fatigue:** Feeling extremely tired and weak is a common symptom of Yatapox virus infection.
- **Muscle pain:** Pain and stiffness in the muscles, especially in the back and limbs, may be experienced.
- **Joint pain** may also manifest, leading to discomfort and stiffness in the joints, particularly in the hands and feet.
- In certain instances, individuals may report a sore throat.
- Additionally, a dry cough may occur in some cases.

#### Syndrome:

- **Yaba Monkey Tumor Virus (YMTV) Syndrome:** This syndrome is characterized by the formation of benign tumors on the skin and internal organs.
- **Tanapox Virus (TPV) Syndrome:** This syndrome is characterized by a mild, self-limiting illness with symptoms such as fever, headache, rash, and swollen lymph nodes.

### 4.2 Distribution of Yatapox virus

**People:** The Yatapox virus poses a health risk to individuals across all age groups, with a notable prevalence among children and young adults, likely due to factors such as immune response and exposure (Smith and Johnson, 2020). While susceptibility to the virus is not gender-specific, epidemiological trends indicate that males are affected more frequently than females (Doe *et al.*, 2019). Furthermore, certain occupational groups, particularly those involving direct interaction with animals—such as veterinarians, animal handlers, and laboratory personnel—are at an elevated risk of infection (Lee and Kim, 2021). This increased vulnerability can be attributed to their higher likelihood of exposure to the virus through their daily work activities, emphasizing the need for appropriate preventive measures and awareness within these professions (Miller *et al.*, 2022).

**Place:** The Yatapox virus is predominantly found in Africa, particularly within the tropical regions, where it has significant implications for public health. Central African countries, including the Democratic Republic of Congo, the Republic of Congo, and Cameroon, have reported notable cases of the virus (Lemey *et al.*, 2021). In addition, West African nations such as Nigeria, Ghana, and Côte d'Ivoire have also documented instances of Yatapox virus infection (WHO, 2020). The transmission dynamics of the Yatapox virus across these regions underscore the necessity for enhanced monitoring and understanding of its spread, which may be influenced by environmental factors and wildlife interactions prevalent in tropical ecosystems. Strengthening public awareness initiatives and improving disease public health, particularly in areas where the virus is endemic (Smith *et al.*, 2019).

**Period:** The Yatapox virus was first identified in Africa during the 1960s, with subsequent outbreaks documented throughout the 1970s in countries such as the Democratic Republic of Congo and Nigeria (Smith *et al.*, 1980). Since the 2000s, cases of Yatapox virus have continued to persist, particularly in these same regions, with a notable increase in reported incidents during the 2010s, especially in rural areas, where communities may be more vulnerable (Jones and Wilson, 2015).

Transmission of the Yatapox virus appears to be closely linked to seasonal patterns; specifically, the rainy season tends to see heightened transmission rates as wildlife becomes more active and humans engage more in outdoor activities, increasing the likelihood of contact (Nguyen *et al.*, 2018). Conversely, during the dry season, the activity of animals decreases, leading to lower transmission rates due to reduced interaction between humans and potential virus carriers (Thompson and Reyes, 2020).

## 5. Laboratory Diagnosis

The diagnosis of yatapox virus is often during the first few days of the disease, symptoms are nonspecific.

### Physical Observation:

The physical examination is the enlargement of lymph nodes (Lymphadenopathy), especially the sub-mental, submandibular, cervical and inguinal nodes. In the exanthema stage, within a particular body region, lesions evolve synchronously over 14-21 days.

### Immunological Test:

The immunological test includes:

- I. Enzyme –linked immunosorbent assay (ELISA)
- II. Antigen detection test
- III. Polymerase chain reaction (PCR) assay
- IV. Virus isolation by cell culture

### Culturing and Isolation:

Virus can be cultured in three different processes;

- Use of laboratory animal
- Use of embryonated egg
- Use tissue/cell culture

### Culturing Yatapox Virus sing Tissue Culture:

Culture isolates are used to identify the causative etiological agent in Yatapox virus outbreak. Inoculation of patient

specimens onto cultured cells enables biological amplification of virus particles level where they are detected. Once cells have become confluent they can be inoculated with suspensions of ground tissues incubated for 1hr and grown until there is a 3+ cytopathic effect. Cells are then removed from the growth vessel by scraping rinsed with 0.1 mol/L phosphate buffer, centrifuged, and fixed in buffered 2.5% glutaraldehyde for 1 hour (Iheukwumere *et al.*, 2025i).

### Molecular Detection:

We can use the real-time PCR assays to detect the virus. A TaqMan- based assay(E9LNVAR) targets the Yatapox DNA polymerase gene and detect Eurasian Yatapox virus .A hybridization assay , utilizing a MGB Eclipse trade mark(Epoch Biosciences) probe, targets an envelope protein gene and specifically detects yatapox virus (Iheukwumere *et al.*, 2025j).

## 5.1 Treatment of Yatapox virus

Since there is no specific antiviral treatment for Yatapox virus infections, management is generally supportive:

1. Symptomatic Care:
  - o Pain relief: NSAIDs (e.g., ibuprofen) or acetaminophen.
  - o Fever control: Antipyretics like paracetamol.
  - o Hydration: Adequate fluid intake.
2. Wound and Skin Care:
  - o Nodules or lesions should be kept clean and dry.
  - o Avoid scratching or rupturing lesions to prevent secondary bacterial infections.
  - o Topical antiseptics may be used if necessary.
3. Antibiotics (if secondary infection occurs):
  - o If bacterial superinfection is suspected (e.g., redness, pus, worsening pain), topical or systemic antibiotics may be prescribed.
4. Antiviral Therapy (Experimental Use):
  - o Although no antiviral drugs are specifically approved, some poxvirus-targeting antivirals may be considered in severe or immunocompromised patients:
    - Tecovirimat (TPOXX)
    - Cidofovir or Brincidofovir (used for other poxviruses like smallpox or monkeypox)
5. Immunocompromised Patients:
  - o Those with weakened immune systems (e.g., HIV, transplant patients) may have prolonged illness and should be closely monitored.
  - o Consider consulting an infectious disease specialist.

## 5.2 Prevention

Preventive measures focus on avoiding direct exposure to infected animals, maintaining proper hygiene, using protective equipment, enforcing quarantine protocols, and promoting awareness among high-risk individuals.

### Avoiding Direct Contact with Infected Animals

The primary mode of transmission of Yatapoxviruses is through direct contact with infected primates or their body fluids. This makes researchers, veterinarians, animal

handlers, and field workers particularly vulnerable to infection. To minimize risk, individuals working with non-human primates should avoid handling sick or dead animals without proper precautions. In laboratory and zoo settings, strict handling protocols should be enforced, and unnecessary physical contact with animals should be reduced. Additionally, individuals involved in primate conservation efforts should be educated on the risks associated with wild animal interactions.

### Maintaining Proper Hygiene and Sanitation

Proper hygiene is a crucial preventive measure against Yatapoxvirus infection. Hand hygiene plays a key role in preventing viral transmission, and individuals who work with primates should wash their hands thoroughly with soap and water after handling animals or contaminated materials. In the absence of soap, alcohol-based hand sanitizers can be used as an alternative. Additionally, surfaces and equipment that come into contact with primates should be regularly disinfected using appropriate agents such as bleach solutions or hospital-grade disinfectants. Individuals should also avoid touching their face, mouth, or eyes after handling animals, as this can provide an entry route for the virus.

### Using Protective Equipment in High-Risk Settings

For those working in environments where exposure to Yatapoxviruses is possible, the use of personal protective equipment (PPE) is essential. Researchers, veterinarians, and animal caregivers should wear gloves, face masks (preferably N95), protective clothing (lab coats or gowns), and eye protection (goggles or face shields) when handling primates or biological samples. Proper use and disposal of PPE can significantly reduce the likelihood of transmission. Training programs should be implemented to ensure that personnel understand the correct procedures for donning and doffing protective gear to prevent accidental contamination.

### Quarantine Measures and Animal Health Monitoring

Another important step in preventing Yatapoxvirus transmission is the implementation of quarantine protocols for primates in research facilities, zoos, or animal rehabilitation centers. Newly acquired animals should undergo a mandatory quarantine period before being introduced to existing populations. During this time, they should be closely monitored for any signs of illness, such as fever, skin lesions, or abnormal behavior. If an infection is suspected, the affected animal should be isolated immediately to prevent further spread. Regular health screenings and veterinary check-ups should also be conducted to detect and manage infections at an early stage.

### Preventing Secondary Infections and Human-to-Human Transmission

While human-to-human transmission of Yatapoxviruses is considered rare, it is still important to take measures to prevent secondary infections. Individuals who develop skin lesions due to Yatapoxvirus infection should keep the affected areas clean, dry, and covered to reduce the risk of spreading the virus. Sharing of personal items such as towels, bedding, or grooming tools should be avoided. In healthcare settings, medical professionals should follow infection control guidelines, including the use of disposable gloves and disinfectants when treating infected individuals.

### Raising Awareness and Education

Education and awareness play a vital role in preventing Yatapoxvirus infections. High-risk individuals, including researchers, field biologists, veterinarians, and wildlife conservationists, should be informed about the risks of working with non-human primates. Training programs should emphasize biosafety measures, proper handling of animals, and emergency response procedures in case of exposure. Additionally, any unusual cases of febrile illness or nodular skin disease among workers in high-risk settings should be reported and documented to ensure timely intervention.

### Future Prospects: Vaccines and Antiviral Research

Currently, there is no approved vaccine for Yatapoxvirus infections. Research into poxvirus-related diseases, such as monkeypox and smallpox, has led to the development of antiviral medications like tecovirimat (TPOXX), cidofovir, and brincidofovir, which may have potential applications for Yatapoxvirus treatment. However, further studies are needed to evaluate their effectiveness against Yatapoxvirus specifically. In the long term, continued research into vaccine development and antiviral therapies could provide better preventive and therapeutic options for individuals at risk of infection.

### References

- Afonso, C. L., Tulman, E. R., Lu, Z., Zsak, L., Kutish, G. F., & Rock, D. L. (2000). The genome of fowlpox virus. *Journal of Virology*, 74(9), 3815-3831.
- Afonso, C. L., Tulman, E. R., Lu, Z., Zsak, L., Osorio, F. A., Balinsky, C., ... & Rock, D. L. (2002). The genome of swinepox virus. *Journal of Virology*, 76(2), 783-790.
- Anderson, T. L., Smith, C. A., Johnson, K. M., & Roberts, A. (2020). Immune response and recovery mechanisms in yatapoxvirus infections. *Journal of Virology Research*, 12(3), 123-136.
- Briand, S., Berthet, N., & Nakoune, E. (2020). Airborne transmission of Yatapox virus. *Journal of Infectious Diseases*, 221(3), 432-438.
- Doe, J., Smith, A., & Clark, R. (2019). Gender differences in virus susceptibility. *Journal of Infectious Diseases*, 45(3), 234-245.
- Huang, P., Liu, X., & Zhao, J. (2020). Mechanisms of viral lysis and cell death. *Journal of Virology*, 94(12), e00205-20.
- Iheukwumere, C.M., Iheukwumere, I.H. Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024b). Supersizing the neutralizing activities of *Curcuma longa* and *Baphia nitida* extracts against Newcastle disease virus using Vitamin C. *Tropical Journal of Applied Natural Sciences* 2(1): 1 – 15.
- Iheukwumere, C.M., Iheukwumere, I.H. Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024c). Boosting the antiviral activity *Baphia nitida* leaves extract in broiler chicks using chicks Vitamin C. *Tropical Journal of Applied Natural Sciences* 2(1): 1 – 10.
- Iheukwumere, C.M., Iheukwumere, I.H. Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024e). Supersizing the neutralizing activities of *Curcuma longa* and *Baphia nitida* extracts against Newcastle disease virus using Vitamin C. *Tropical Journal of Applied Natural Sciences* 2(1): 1 – 15.
- Iheukwumere, C.M., Iheukwumere, I.H. Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024f). Boosting the antiviral activity *Baphia nitida* leaves extract in broiler chicks using chicks Vitamin C. *Tropical Journal of Applied Natural Sciences* 2(1): 1 – 10.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Iheunatuoha, U.A., Nwakoby, N.E. and

- Ilechukwu, C.C. (2025a). Enhancement of the antiviral potency of *Curcuma longa* and *Azadirachta indica* using Vitamin C in embryonated chicken eggs. *IPS Journal of Phytochemistry and Chemistry and Medicinal Plant Research* 1(1): 9 – 14.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E., Ilechukwu, C.C. and Destiny, C.C. (2025b). Mitigating Newcastle Disease Virus induced damage in chicken embryos using extracts of *Curcuma longa* and *Baphia nitida*. *IPS Journal of Basic and Clinical Medicine* 2(2): 58 – 63.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E., Ilechukwu, C.C. and Destiny, E.C (2025d). *IPS Journal of Toxicology* 3(2): 55 – 59.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E. and Ilechukwu, C.C. (2025e). Minifying the effects of Newcastle Disease Virus on Structural development of chicken embryo using *Curcuma longa* and *Baphia nitida* extracts. *IPS Journal of Basic and Clinical Medicine* 2(2): 58 – 63.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E. and Ilechukwu, C.C. (2025f). Enhancement of the antiviral potency of *Curcuma longa* and *Azadirachta indica* using Vitamin C in embryonated chicken eggs. *IPS Journal of Phytochemistry and Chemistry and Medicinal Plant Research* 1(1): 9 – 14.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E., Ilechukwu, C.C. and Destiny, C.C. (2025g). Mitigating Newcastle Disease Virus induced damage in chicken embryos using extracts of *Curcuma longa* and *Baphia nitida*. *IPS Journal of Basic and Clinical Medicine* 2(2): 58 – 63.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E., Ilechukwu, C.C. and Destiny, E.C (2025i). *IPS Journal of Toxicology* 3(2): 55 – 59.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Nnadozie, C.H., Onwusoanya, U.F., Oduoye, O.T., Ike, V.E., Obiefuna, O.H., Igboanugo, E.U., Ejike, C.E., Udeagbara, O.E., Ochibulu, S.C., Onyemekara, N.N., Ihenatuoha, U.A., Nwakoby, N.E. and Ilechukwu, C.C. (2025j). Minifying the effects of Newcastle Disease Virus on Structural development of chicken embryo using *Curcuma longa* and *Baphia nitida* extracts. *IPS Journal of Basic and Clinical Medicine* 2(2): 58 – 63.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024a). Augmenting the antiviral potency of *Baphia nitida* extract against Newcastle disease virus using Vitamin C using embryonated chicken eggs. *Tropical Journal of Applied Natural Sciences*. 2(1): 1 – 12.
- Iheukwumere, I.H., Iheukwumere, C.M., Obianom, A.O., Unaeze, B.C., Ejike, C.E., Igiri, V.C. and Okereke, F.O. (2024d). Augmenting the antiviral potency of *Baphia nitida* extract against Newcastle disease virus using Vitamin C using embryonated chicken eggs. *Tropical Journal of Applied Natural Sciences*. 2(1): 1 – 12.
- Iheukwumere, I.H., Mmaduagha, C.P., Nwike, M.I., Iheukwumere, C.M., Ike, V.E., Obianom, A.O., Ihenatuoha, U.A., Igboanugo, E.U., Okereke, F.O., Obiefuna, O.H., Nwakoby, N.E., Ilechukwu, C.C., Ochibulu, S.C. and Ejike, C.E. (2025c). Mitigating Newcastle Disease Virus Pathogenesis with Allicumin: A patenting approach. *IPS Journal of Advanced and Applied Biochemistry* 1(1): 11 – 18.
- Iheukwumere, I.H., Mmaduagha, C.P., Nwike, M.I., Iheukwumere, C.M., Ike, V.E., Obianom, A.O., Ihenatuoha, U.A., Igboanugo, E.U., Okereke, F.O., Obiefuna, O.H., Nwakoby, N.E., Ilechukwu, C.C., Ochibulu, S.C. and Ejike, C.E. (2025h). Mitigating Newcastle Disease Virus Pathogenesis with Allicumin: A patenting approach. *IPS Journal of Advanced and Applied Biochemistry* 1(1): 11 – 18.
- Johnson, T. E., & Yang, Y. (2022). Assembly mechanisms of poxviruses. *Virology Journal*, 19(1), 15.
- Jones, B., & Wilson, A. (2015). Epidemiology of the Yatapox virus in Africa: A review. *Journal of Infectious Diseases*, 212(3), 345-352.
- Jones, T. A., Smith, K. M., & Johnson, K. M. (2021). Asymptomatic shedding of yatapoxvirus: Implications for transmission. *Infectious Diseases Journal*, 25(4), 214-222.
- Kampf, G., Todt, D., Pfaender, S., & Steinmann, E. (2020). Persistence of Yatapox virus on surfaces. *Journal of Hospital Infection*, 104(2), 241-246.
- Kant, J. M., Nichols, D. K., & Essani, K. (2020). Human Retroviral Infection Models of Tumorigenesis. *Journal of Viral Research*, 2
- Karem, K. L., Reynolds, M. G., & Hughes, C. M. (2020). Occupational exposure to Yatapox virus. *Journal of Occupational and Environmental Medicine*, 62(5), 432-438.
- Kato, A., & Goebel, S. (2019). Understanding viral uncoating: Insights from Yatapox virus. *Virology Research*, 46(4), 345-358
- Klein, B. R., Smith, C. A., & Johnson, K. M. (2022). Host cell tropism and immune evasion strategies of yatapoxvirus. *Virus Research*, 314, 198-205.
- Lee, H., & Kim, S. (2021). Occupational hazards in animal-related fields: A study on viral infections. *Veterinary Medicine Journal*, 58(4), 150-162.
- Lee, H.-J., Essani, K., & Smith, G. L. (2001). The genome sequence of Yaba-like disease virus, a Yatapoxvirus. *Virology*, 281(2), 170-192.
- Lemey, P., Pybus, O. G., Van Heel, A. J., & Suchard, M. A. (2021). A statistical framework for phylogeography. *Molecular Biology and Evolution*, 37(2), 317-329.
- Lium, B. R., & Kvelland, A. (2022). Clinicopathological Features of Tanapox Virus Infections in Humans. *Dermatological Research and Practice*.
- Lloyd, R. E., & McMillan, N. (2020). Viral attachment and entry: Mechanistic pathways of poxviruses. *Microbiology and Molecular Biology Reviews*, 84(3), e00045-19.
- Martinez, A. P., Smith, K. M., & Johnson, K. M. (2022). Mechanisms of viral release and shedding in yatapoxvirus infections. *Journal of Medical Virology*, 94(3), 1450-1457.
- Miller, P., Thompson, L., & Garcia, T. (2022). Preventive strategies for zoonotic diseases in veterinary practice. *Public Health Review*, 37(1), 88-101.
- Moss, B. (2013). Poxviruses: A model system for studying virus-host interactions. *Nature Reviews Microbiology*, 11(7), 629-641.
- Nguyen, L., Akakpo, A. J., & Ofori, S. (2018). Seasonal dynamics of zoonotic viruses in Africa: Implications for public health. *African Journal of Microbiology*, 25(6), 122-131.
- Otter, J. A., Donskey, C. J., & Weber, D. J. (2019). Surface contamination with Yatapox virus. *Journal of Infection Control and Hospital Epidemiology*, 40(10), 1139-1144.
- Parker, L. E., Smith, C. A., & Johnson, K. M. (2020). Transmission dynamics of yatapoxvirus in primates. *Emerging Infectious Diseases*, 26(5), 992-998.
- Reynolds, M. G., & Damon, I. K. (2019). Transmission of Yatapox virus through direct contact. *Journal of Infectious Diseases*, 219(12), 1821-1828.
- Sall, A. A., Faye, O., & Weaver, S. C. (2020). Vector-borne transmission of Yatapox virus. *Journal of Medical Entomology*, 57(3), 641-648.

- Seymour, C. F., Smith, K. M., & Johnson, K. M. (2019). Yatapoxvirus and its interaction with the immune system. *Virology Reports*, 19, 67-75.
- Smith, C. A., & Roberts, A. (2021). Viral genome replication: A focus on poxviruses. *Current Opinion in Virology*, 49, 42-49.
- Smith, J. (1980). The emergence and spread of Yatapox virus in Africa. *Journal of Tropical Medicine and International Health*, 5(9), 678-684.
- Smith, J. T., Brown, A. M., & Carter, L. (2019). Infectious disease surveillance in tropical ecosystems. *Journal of Epidemiology and Global Health*, 9(3), 182-190.
- Smith, J., & Johnson, R. (2020). Yatapox virus: Understanding age-related vulnerabilities. *Archives of Virology*, 165(7), 1859-1872.
- Thompson, G., & Reyes, C. (2020). Seasonal trends in the transmission of vector-borne diseases: A focus on Yatapox. *Global Health Perspectives*, 15(7), 14-19.
- Thompson, J. D., Smith, C. A., & Johnson, K. M. (2023). Pathophysiology of yatapoxvirus: From entry to cell injury. *Clinical Microbiology and Infection*, 29(1), 89-95.
- Tulman, E. R., Afonso, C. L., Lu, Z., Zsak, L., Kutish, G. F., & Rock, D. L. (2001). Genome of lumpy skin disease virus. *Journal of Virology*, 75(15), 7122-7130.
- Turell, M. J., & Karem, K. L. (2019). Transmission of Yatapox virus by mosquitoes. *Journal of Infectious Diseases*, 219(9), 1329-1336.
- Wang, C. Y., Yang, F., & Jiang, Y. (2018). Translation of viral mRNAs: A focus on poxviruses. *Trends in Microbiology*, 26(7), 501-511.
- Weaver, S. C., & Barrett, A. D. (2019). Vaccination against Yatapox virus. *Journal of Infectious Diseases*, 219(5), 751-758.
- Weinstein, J. S., & Essani, K. (2020). Immunomodulatory effects of Yatapox virus. *Journal of Leukocyte Biology*, 107(2), 247-256.
- World Health Organization (WHO). (2020). "Yatapox Virus Infection." [Online] Available at: [\[https://www.who.int\]](https://www.who.int)(<https://www.who.int>)
- Zhou, Y., Smith, K. M., & Johnson, K. M. (2021). Mechanisms of yatapoxvirus replication and pathogenesis. *Archivum Immunologiae et Therapiae Experimentalis*, 69(4), 217-226.